Fintel reports that on January 28, 2026, Cantor Fitzgerald upgraded their outlook for Korro Bio (NasdaqCM:KRRO) from Neutral to Overweight. As of January 14, 2026, the average one-year price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results